Posted by Michael Wonder on 13 Jan 2021
Regeneron announces U.S. Government agreement to purchase additional COVID-19 antibody cocktail doses
12 January 2021 - New agreement covers 1.25 million additional doses of the casirivimab and imdevimab antibody cocktail, bringing total potential U.S. supply to over 1.5 million doses.
Regeneron Pharmaceuticals today announced that the U.S. Department of Health and Human Services and the Department of Defense will purchase additional supply of the casirivimab and imdevimab antibody cocktail for use in non-hospitalised COVID-19 patients to meet the federal government's Operation Warp Speed goals.
The Government has said it will provide these doses at no cost to patients, though healthcare facilities may charge fees related to administration.
